Current treatments controlling oxygen-regulated factors such as vascular endothelial cell growth factor (VEGF) focus on the late vision-threatening uncontrolled retinal vessel growth (Phase II ROP) [2,3,4]. Here, VEGFA is linked to retinopathy of prematurity.